Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 178 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Holidays and Hope When a Loved One Has Advanced Cancer December 20, 2023 Health of Gut Microbes May Affect Survival after Stem Cell Transplant March 25, 2020 Young District Attorney Diagnosed with Breast Cancer Encourages Others to Get... November 30, 2020 EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 Load more HOT NEWS GreaterGood Is Donating Thousands of Masks to Help Animal Shelters Stay... Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer Aspirin Being Investigated as Possible Treatment for Triple Negative Breast Cancer First Prospective Description of Familial EGFR-mutated Lung Cancer
